

DAFTAR PUSTAKA

- Abbas, A. (2017). Monitoring efek samping obat anti-tuberkulosis (OAT) pada pengobatan tahap intensif penderita TB paru di Kota Makassar. *Journal of Agromedicine and Medical Sciences*, 3(1), 19–24.
- Adiputra, I. M. S., Trisnadewi, N. W., Oktaviani, N. P. W., Munthe, S. A., Hulu, V. T., Budiastutik, I., Faridi, A., Ramdany, R., Fitriani, R. J., Tania, P. O. A., Rahmiati, B. F., Lusiana, S. A., Sianturi, E., & Suryana. (2021). *Metodologi penelitian kesehatan*. Yayasan Kita Menulis.
- Agustin, R. A. (2018). *Tuberkulosis*. Deepublish.
- Alexopoulou, A., Dourakis, S. P., Mantzoukis, D., Pitsariotis, T., Kandyli, A., Deutsch, M., & Archimandritis, A. J. (2008). Adverse drug reactions as a cause of hospital admissions: A 6-month experience in a single center in Greece. *European Journal of Internal Medicine*, 19(7), 505–510.
- American Society of Health-System Pharmacists. (2011). *AHFS drug information 2011*. American Society of Health-System Pharmacists.
- Anggraini, S. (2016). *Analisis potensi interaksi obat penyakit tuberkulosis paru pada pasien dewasa di BP4 Pontianak* [Skripsi, Universitas Tanjungpura].
- Athira, B., Cs, M., & Jyothi, E. (2015). A study on adverse drug reactions to first line antitubercular drugs in DOTS therapy. *International Journal of Pharmacology and Clinical Sciences*, 4(1), 7–11.
- Aziz, K. K. (2019). Pengobatan tuberkulosis paru dan diabetes melitus serta pengaruhnya terhadap risiko MDR-TB. *Anatomica Medical Journal*, 2(1), 22–32.
- Bories, M., Bouzillé, G., Cuggia, M., & Le Corre, P. (2021). Drug–drug interactions in elderly patients: A systematic review. *Pharmaceutics*, 13(2), 1–15.
- Brunner, S. (2016). *Buku ajar keperawatan medikal bedah Brunner & Suddarth* (Edisi 8). EGC.
- Gujjarlamudi, H. B. (2016). Polytherapy and drug interactions in elderly. *Journal of Mid-Life Health*, 7(3), 105–107.

- Handayani, I., & Sumarni. (2021). *Tuberkulosis*. Penerbit NEM.
- Herdaningsih, S., Muhtadi, A., Lestari, K., & Annisa, N. (2016). Potential of drug–drug interaction in polypharmacy prescription. *Indonesian Journal of Clinical Pharmacy*, 5(4), 288–292.
- Horn, J. R., & Hansten, P. D. (2007). *Drug Interaction Probability Scale (DIPS): A method for assessing causal relationships in drug interactions*. *Annals of Pharmacotherapy*, 41(4), 674–680.
- Hulu, V. T., Salman, S., Supinganto, A., Amalia, L., Khariri, K., Sianturi, E., Nilasari, N., Siagian, N., Hastuti, P., & Syamdarniati, S. (2020). *Epidemiologi penyakit menular*. Yayasan Kita Menulis.
- Kementerian Kesehatan Republik Indonesia. (2020). *Pedoman nasional pengendalian tuberkulosis*. Kementerian Kesehatan RI.
- Kementerian Kesehatan Republik Indonesia. (2022). *Profil kesehatan Indonesia tahun 2022*. Kementerian Kesehatan RI.
- Lönnroth, K., Castro, K. G., Chakaya, J. M., Chauhan, L. S., Floyd, K., Glaziou, P., & Raviglione, M. (2019). Tuberculosis control and elimination: Cure, care, and social development. *The Lancet*, 375(9728), 1814–1829.
- Lukito, P. K. (2020). *Modul farmakovigilans bagi tenaga profesional kesehatan*. Badan Pengawas Obat dan Makanan RI.
- Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., & Menzies, D. (2016). Official clinical practice guidelines: Treatment of drug-susceptible tuberculosis. *Clinical Infectious Diseases*, 63(7), e147–e195.
- Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981). A method for estimating the probability of adverse drug reactions. *Clinical Pharmacology & Therapeutics*, 30(2), 239–245.
- Panahi, Y., Hosseini, M. S., Khalili, N., Naimi, E., Majeed, M., & Sahebkar, A. (2019). Curcumin as a hepatoprotective agent: A systematic review. *Phytotherapy Research*, 33(4), 985–995.

- Ramappa, V., & Aithal, G. P. (2013). Hepatotoxicity related to anti-tuberculosis drugs: Mechanisms and management. *Journal of Clinical and Experimental Hepatology*, 3(1), 37–49.
- Restrepo, B. I. (2016). Diabetes and tuberculosis. *Microbiology Spectrum*, 4(6), 1–17.
- Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., Schenker, S., Jereb, J. A., Nolan, C. M., Peloquin, C. A., Gordin, F. M., Nunes, D., Strader, D. B., Bernardo, J., & Venkataramanan, R. (2018). An official ATS statement: Hepatotoxicity of antituberculosis therapy. *American Journal of Respiratory and Critical Care Medicine*, 198(5), 559–565.
- Tostmann, A., Boeree, M. J., Aarnoutse, R. E., de Lange, W. C. M., van der Ven, A. J. A. M., & Dekhuijzen, R. (2008). Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. *Journal of Gastroenterology and Hepatology*, 23(2), 192–202.
- WHO. (2022). *WHO consolidated guidelines on tuberculosis: Module 4 – Treatment*. WHO.
- WHO. (2023). *Global tuberculosis report 2023*. WHO.